Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II)

Journal of Urology

Volumn 160, Issue 2, 1998, Pages 561-570

  Mizutani, Youichi ^a   Yoshida, Osamu ^b   Bonavida, Benjamin ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Apoptosis; Bladder cancer; CDDP; Fas; Synergy

Indexed keywords

CARBOPLATIN; CISPLATIN; FAS LIGAND; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; TRANSPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

EID: 0032322332     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62959-8     Document Type: Article

References (52)

1. Safrit, J. T. and Bonavida, B.: Hierarchy of sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs, and toxins. Cancer Immunol. Immunother., 34: 321, 1992.
2. Bonavida, B., Tsuchitani, T., Safrit, J. T. and Zighelboim, J.: Hierarchy of tumor cell sensitivity and resistance to cytolysis by TNF, cytotoxic cells, bacterial toxins, and cytotoxic drugs. In: Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. Edited by B. Bonavida and G. Granger. Basel: Karger, pp. 125-132, 1990.
3. Birkhead, B. G.: Evaluating and designing cancer chemotherapy treatment using mathematical models. Eur. J. Cancer Clin. Oncol., 22: 3, 1986.
4. Mizutani, Y. and Bonavida, B.: Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α. Cancer, 72: 809, 1993.
5. Safrit, J. T. and Bonavida, B.: Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res., 52: 6630, 1992.
6. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. and Golstein, P.: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265: 528, 1994.
7. Arase, H., Arase, N. and Saito, T.: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med., 181: 1235, 1995.
8. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponstingl, H. and Krammer, P. H.: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J. Biol. Chem., 267: 10709, 1992.
9. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S. I., Sameshima, M., Hase, A., Seto, Y. and Nagata, S.: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233, 1991.
10. Watanabe-Fukunaga, R., Brannan, C. I., Itoh, N., Yonehara, S., Copeland, N. G., Jenkins, N. A. and Nagata, S.: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol., 148: 1274, 1992.
11. Nagata, S.: Fas and Fas ligand: a death factor and its receptor. Adv. Immunol., 57: 129, 1994.
12. Suda, T., Takahashi, T., Golstein, P. and Nagata, S.: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169, 1993.
13. Smith, C. A., Farrah, T. and Goodwin, R. G.: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76: 959, 1994.
14. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. and Nagata, S.: Lethal effect of the anti-Fas antibody in mice. Nature, 364: 806, 1993.
15. Trauth, B. C., Klas, C., Peters, A. M. J., Matzuku, S., Moller, P., Falk, W., Debatin, K. M. and Krammer, P. H.: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245: 301, 1989.
16. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer, 69: 537, 1992.
17. Mizutani, Y., Okada, Y., Terachi, T., Kakehi, Y. and Yoshida, O.: Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies. Br. J. Urol., 76: 580, 1995.
18. Mizutani, Y., Okada, Y., Terachi, T. and Yoshida, O.: Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with urinary bladder cancer. J. Urol., 155: 888, 1996.
19. Mizutani, Y., Nio, Y. and Yoshida, O.: The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer, 69: 2999, 1992.
20. Mizutani, Y. and Yoshida, O.: Overcoming TNF-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and TNF-α. Role of TNF-α mRNA downregulation in tumor cell sensitization. Cancer, 73: 730, 1994.
21. Mizutani, Y., Fukumoto, M., Bonavida, B. and Yoshida, O.: Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer, 74: 1546, 1994.
22. Murai, N., Ueda, T., Takahashi, J., Yang, H., Kikuchi, H., Hatanaka, M. and Fukumoto, M.: Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J. Neurosurgery, 85: 1072, 1996.
23. Daley-Tates, P. T. and McBrien, D. C. H.: A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem. Pharmacol., 34: 2263, 1985.
24. Riley, C. M., Sternson, L. A. and Repta, A. J.: Assessment of cisplatin reactivity with peptides and proteins using reversephase high-performance liquid chromatography and flameless atomic absorption spectroscopy. Anal. Biochem., 124: 167, 1982.
25. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida, O.: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res., 55: 590, 1995.
26. Mizutani, Y., Bonavida, B., Nio, Y. and Yoshida, O.: Overcoming TNF-α and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-α or drugs. J. Urol., 151: 1697, 1994.
27. Mizutani, Y., Nio, Y., Bonavida, B. and Yoshida, O.: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer, 71: 1313, 1993.
28. Berenbaum, M. C.: Synergy, additivism and antagonism in immunosuppression. Clin. Exp. Immunol., 28: 1, 1977.
29. Berenbaum, M. C.: A method for testing for synergy with any number of agents. J. Infect. Dis., 137: 122, 1978.
30. Teicher, B. A., Holden, S. A., Kelly, M. J., Shea, T. C., Cucchi, C. A., Roswsky, A., Henner, W. D. and Frei, E.: Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res., 47: 388, 1987.
31. Nakagawa, K., Yokota, J. and Wada, M.: Levels of glutathione S-transferase π mRNA in human lung cancer cell lines correlative with the resistance to cisplatin and carboplatin. Jpn. J. Cancer Res., 79: 301, 1988.
32. Richon, V. M., Schulte, N. and Eastman, A.: Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res., 47: 2056, 1987.
33. Waud, W. R.: Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res., 47: 6549, 1987.
34. Mizutani, Y. and Bonavida, B.: Overcoming TNF-α and CDDP resistance of a human ovarian cancer cell line (C30) by treatment with buthionine sulfoximine in combination with TNF-α and/or CDDP. Int. J. Oncol., 3: 229, 1993.
35. Hromas, R. A., Andrews, P. A., Murphy, M. P. and Burns, C. P.: Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett., 34: 9, 1987.
36. Andrews, P. A., Murphy, M. P. and Howell, S. B.: Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 19: 149, 1988.
37. Taylor, D. M., Tew, K. D. and Jones, J. D.: Effects of cis-dichlorodiammineplatinum (II) on DNA synthesis in kidney and other tissues of normal and tumor-bearing rats. Eur. J. Cancer, 12: 249, 1976.
38. Roos, I. A. G. and Arnold, M. C.: Interaction of an anti-tumor active platinum complex with DNA. J. Clin. Hematol. Oncol., 7: 374, 1977.
39. Pera, M. F., Rawlings, C. J. and Roberts, J. J.: The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem. Biol. Interact., 37: 245, 1981.
40. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K. and Yonehara, S.: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54: 1580, 1994.
41. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J. and Mountz, J. D.: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 263: 1759, 1994.
42. Itoh, N., Tsujimoto, Y. and Nagata, S.: Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol., 151: 621, 1993.
43. Sentman, C. L., Shutter, J. R., Hockenberry, D., Kanagawa, O. and Korsmeyer, S. J.: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67: 879, 1991.
44. Sato, T., Irie, S., Kitada, S. and Reed, J. C.: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science, 268: 411, 1995.
45. Mori, S., Mori, K., Jewett, A., Nakamura, S. and Bonavida, B.: Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res., 56: 1874, 1996.
46. Connors, T. A., Cleare, M. J. and Harrap, K. R.: Structure activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep., 63: 1499, 1979.
47. Harrap, K. R., Jones, M., Wilkinson, C. R., Clink, H. M., Sparrow, S., Mitchley, B., Clarke, S. and Veasey, A.: Antitumor, toxic, and biochemical properties of cisplatin and eight other platinum complexes. In: Cisplatin: Current Status and New Developments. Edited by A. W. Prestayko, S. T. Cooke and S. K. Carter. New York: Academic Press, Inc., pp. 193-212, 1980.
48. Zwelling, L. A., Kohn, K. W., Ross, W. E., Ewig, R. A. G. and Anderson, T.: Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum (II). Cancer Res., 38: 1762, 1978.
49. Pascoe, J. M. and Roberts, J. J.: Interactions between mammalian cell DNA and inorganic platinum compounds. Biochem. Pharmacol., 23: 1345, 1974.
50. Kerr, J. F. R., Winterford, C. M. and Harmon, B. V.: Apoptosis. Cancer, 73: 2013, 1994.
51. Barry, M. A., Behnke, C. A. and Eastman, A.: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353, 1990.
52. Shima, Y., Nishio, N., Ogata, A., Fujii, Y., Yoshizaki, K. and Kishimoto, T.: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood, 85: 757, 1995.